John M. Burke, MD, turns to ChatGPT to uncover what artificial intelligence may do for hematologists/oncologists.
Artificial intelligence (AI) is all the rage. Although AI has been a part of our lives for a long time, the release of the online chatbot ChatGPT by the company OpenAI on November 30, 2022, has ushered in a new era of enthusiasm about the potential for AI to improve our lives. If you haven’t tried ChatGPT yet, you’re probably one of the few. Based on current estimates, the ChatGPT website has approximately 25 million visitors daily. Microsoft has invested $10 billion in OpenAI. Google has announced that it will be incorporating conversational AI into its search engine. And in medicine, the New England Journal of Medicine has announced that it is planning a new online journal called NEJM AI “to identify and evaluate state-of-the-art applications of artificial intelligence to clinical medicine.”
What could AI do for physicians in general and hematologists/oncologists in particular? To answer that question, I turned to ChatGPT itself.
First, AI could help radiologists read scans better and reduce the rates of false-positive and false-negative results, thereby detecting malignant tumors on imaging studies more accurately. Second, in the era of targeted therapies, AI could identify biomarkers and help physicians choose correct treatments.
Third, AI could improve remote monitoring of patients by interpreting data from wearable devices. This feature would be particularly useful as we start to use bispecific antibodies and monitor patients’ vital signs carefully for signs of cytokine release syndrome, but it would also help patients who are receiving conventional chemotherapy.
Fourth, AI-powered robots could assist surgeons performing operations, enabling a greater degree of precision and accuracy. Fifth, chatbots could listen to a visit between physician and patient and write a note summarizing the content.
Sixth, chatbots can already help us think through diagnostic challenges presented by patients. For example, I asked ChatGPT what diagnoses I should consider for a patient reporting blisters on the back of her hands. It listed a differential diagnosis of 6 conditions (although it failed to mention porphyria cutea tarda, which is what I was thinking).
I’m sure there are countless more examples of tasks that AI could help physicians with. In fact, this entire article about AI in oncology could have been written for me in approximately 10 seconds by ChatGPT. I know this because I tried it, and it worked. But I didn’t publish that version. That would be cheating.
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers
December 20th 2024During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.
Read More
Participants Discuss Frontline Immunotherapy Followed by ADC for Metastatic Cervical Cancer
December 19th 2024During a Case-Based Roundtable® event, Ramez N. Eskander, MD, and participants discussed first and second-line therapy decisions for a patient with PD-L1–positive cervical cancer in the frontline metastatic setting.
Read More
Oncologists Discuss a Second-Generation BTK for Relapsed/Refractory CLL
December 18th 2024During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed chronic lymphocytic leukemia after receiving venetoclax and obinutuzumab.
Read More